Analyst Expectations For Harmony Biosciences's Future
Portfolio Pulse from Benzinga Insights
Analysts have mixed views on Harmony Biosciences (NASDAQ:HRMY) with 4 analysts rating it bullish over the past three months. The average 12-month price target is $51.0, slightly down from $52.0. The company shows strong financial performance with significant revenue growth, high net margin, and effective debt management.
August 06, 2024 | 8:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have mixed views on Harmony Biosciences with 4 analysts rating it bullish over the past three months. The average 12-month price target is $51.0, slightly down from $52.0. The company shows strong financial performance with significant revenue growth, high net margin, and effective debt management.
The mixed analyst ratings and slight decrease in the average price target suggest cautious optimism. However, the company's strong financial performance, including significant revenue growth, high net margin, and effective debt management, indicates a positive short-term outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100